Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating untreated locally advanced or metastatic gastric or gastro-oesophageal junction cancer.
As you will be aware the Department for Health and Social Care has NICE to carry out a Single Technology Appraisal of pembrolizumab within its marketing authorisation for treating gastric or gastroesophageal junction adenocarcinoma. Following on from advice received from the company, with regards to the latest results of the KEYNOTE-062 phase 3 study evaluating KEYTRUDA® (pembrolizumab) as monotherapy and in combination with chemotherapy for first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, NICE has decided to temporarily suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process STA 2018
ID number 1305

Provisional Schedule

Committee meeting: 1 18 March 2020

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 June 2019 Suspended, As you will be aware the Department for Health and Social Care has NICE to carry out a Single Technology Appraisal of pembrolizumab within its marketing authorisation for treating gastric or gastroesophageal junction adenocarcinoma. Following on from advice received from the company, with regards to the latest results of the KEYNOTE-062 phase 3 study evaluating KEYTRUDA¬ģ (pembrolizumab) as monotherapy and in combination with chemotherapy for first-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, NICE has decided to temporarily suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
07 December 2018 Following an update from the company, NICE has rescheduled the appraisal and it is expected to begin in mid-July 2019.
18 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for gastric or gastroesophageal junction adenocarcinoma. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early November 2018.
31 January 2018 - 28 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
24 April 2017 In progress, DH referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance